Merck & Co., Inc. - 02 Jun 2021 Form 4 Insider Report for Organon & Co. (OGN)

Reporting relationship: 10%+ Owner
Issuer ticker: OGN
Reported as of: 02 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2021, 16:46:45 UTC
Prior SEC filing: 07 May 2021
Next SEC filing: 17 Jan 2024
Source filing: View source filing
Reporting owner signature: Merck & Co., Inc. /s/ Kelly E.W. Grez, Deputy Corporate Secretary

Key filing fact

Merck & Co., Inc. filed Form 4 for Organon & Co. (OGN) on 04 Jun 2021.

Key facts

This page summarizes Merck & Co., Inc.'s Form 4 filing for Organon & Co. (OGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Jun 2021, 16:46.

Change

Previous filing in this sequence was filed on 07 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OGN transaction

Common Stock

Other

Transaction value
Shares: -253,516,000
Change %: -100%
Price
Shares after: 0
Date: 02 Jun 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Merck & Co., Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation").

Footnote F2

In connection with the Separation, the 100 shares of common stock of Organon & Co. held by Merck were reclassified into 253,516,000 shares of common stock of Organon & Co.